PYTX-004

About Papyrus Therapeutics

Papyrus Therapeutics is pioneering a novel therapeutic modality: protein replacement of tumor suppressors, a historically 'undruggable' target class. Its lead program, PYTX-004, is an OPCML-Fc fusion protein that selectively deactivates multiple receptor tyrosine kinases (RTKs) to collapse cancer signaling pathways, showing potent monotherapy and combination efficacy in preclinical models. The company is IND-enabling for ovarian cancer, with a strong IP position and a leadership team with deep oncology and drug development experience. Papyrus aims to create an entirely new category of cancer therapeutics with a potentially favorable safety profile.

About Papyrus Therapeutics

Papyrus Therapeutics is pioneering a novel therapeutic modality: protein replacement of tumor suppressors, a historically 'undruggable' target class. Its lead program, PYTX-004, is an OPCML-Fc fusion protein that selectively deactivates multiple receptor tyrosine kinases (RTKs) to collapse cancer signaling pathways, showing potent monotherapy and combination efficacy in preclinical models. The company is IND-enabling for ovarian cancer, with a strong IP position and a leadership team with deep oncology and drug development experience. Papyrus aims to create an entirely new category of cancer therapeutics with a potentially favorable safety profile.

Therapeutic Areas